Icosavax, Inc.
ICVXDelisted Feb 20, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001786255
Icosavax, Inc. was delisted on Feb 20, 2024; its insiders filed their last Form 4 on Feb 20, 2024; 93 institutions reported holding it in 13F filings for Q4 2023, worth $663.0M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:18 PM ET
Revenue flow, FY2022
Where the revenue went in FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2022: $91.8M (15766.0% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 |
|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K |
| Reported | Mar 30, 2023 | Jan 7, 2022 |
| Revenue | $582.0K | $7.80M |
| Operating expenses | $95.6M | $73.7M |
| Research and development | $65.4M | $38.8M |
| Selling, general and administrative | $30.2M | $34.9M |
| Operating income | -$95.1M | -$65.9M |
| Interest expense | – | $263.0K |
| Net income | -$91.8M | -$67.0M |
| EPS, basic | $-2.31 | – |
| EPS, diluted | $-2.31 | – |
| Weighted shares, basic | 39.7M | – |
| Weighted shares, diluted | 39.7M | – |
| Margins and growth | ||
| Operating margin | -16333.0% | -844.2% |
| Net margin | -15766.0% | -858.4% |
| Revenue growth, year over year | −92.5% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 |
|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K |
| Reported | Mar 30, 2023 | Jan 7, 2022 |
| Cash and equivalents | $58.8M | $279.1M |
| Short-term investments | $159.5M | – |
| Total current assets | $223.9M | $286.6M |
| Property, plant and equipment | $11.5M | $1.08M |
| Total assets | $238.7M | $287.6M |
| Total current liabilities | $13.8M | $9.24M |
| Total liabilities | $20.5M | $9.41M |
| Shareholders' equity | $218.2M | $278.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2022 | FY2021 |
|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K |
| Reported | Mar 30, 2023 | Jan 7, 2022 |
| Operating cash flow | -$61.7M | -$38.5M |
| Capital expenditures | $11.1M | $1.01M |
| Free cash flow | -$72.8M | -$39.5M |
| Stock-based compensation | $21.7M | $29.0M |
| Investing cash flow | -$169.4M | -$1.01M |
| Financing cash flow | $10.3M | $304.8M |
| Ratio | ||
| Stock-based compensation, % of revenue | 3727.5% | 372.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.